CME's role in FDA opioid safety plan

Share this article:
Margaret Hamburg
Margaret Hamburg

CME providers may see a modest uptick in funding from the FDA's new safety plan for extended-release and long-acting opioids but may be hard-pressed to attract physicians.

The risk evaluation and mitigation strategy (REMS), the agency's first class-wide REMS, requires drugmakers to make CME available to all DEA-registered prescribers of these drugs at no-to-nominal cost to the learner, based on an FDA blueprint. The plan affects more than 20 manufacturers and more than 30 products, such as Purdue Pharma's OxyContin, Endo Pharma's Opana ER and Janssen's Nucynta ER.

A group of pharmas set up a structure for grants and will support CME providers through a website and call center. A number of ACCME- and state-accredited education providers plan to apply.

Dr. Murray Kopelow, the chief executive of the ACCME pointed to a survey of such groups, taken earlier this year showing 78% plan to do CME in support of REMS. Only half of 121 respondents said they will apply for commercially supported CME, most of them for activities designed to familiarize prescribers with how to initiate therapy, modify dose and discontinue use.

Getting physicians up to speed won't be easy. There is no mandatory requirement that prescribers attend the training sessions.

Said Margaret Hamburg, FDA commissioner, “By the third year of the program, we expect that at least 60% of the currently 320,000 prescribers of long-acting opioids in the country will receive the training. We of course would like to see the number even higher.”

The Obama Administration endorsed but has not introduced legislation for a mandatory training program, and the FDA backed off a mandatory plan, even though it was urged to adopt one in 2010 by an independent panel. Hamburg said she hopes Congress will make it compulsory in the future.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.